Therefore, if BCL2A1 expression can be objectively quantified in the EPM, it could not only allow for an accurate assessment of the stage progression (or involved region) and grade (or intensity) in acute HCA but also enhances its value as a therapeutic target for this condition. This evidence concerns the gene BCL2A1 and hepatocellular adenoma.